Cargando…

Association of Smoking With Patient Characteristics and Outcomes in Small Cell Lung Carcinoma, 2011-2018

IMPORTANCE: Small cell lung carcinoma (SCLC) is uncommon in individuals who have never smoked (never-smokers). The related epidemiologic factors and prognosis remain unclear. OBJECTIVE: To assess the epidemiologic factors, clinical characteristics, and outcomes of SCLC in never-smokers. DESIGN, SETT...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tseng, Jeng-Sen, Chiang, Chun-Ju, Chen, Kun-Chieh, Zheng, Zhe-Rong, Yang, Tsung-Ying, Lee, Wen-Chung, Hsu, Kuo-Hsuan, Huang, Yen-Hsiang, Liu, Tsang-Wu, Hsia, Jiun-Yi, Chang, Gee-Chen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2022
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8968543/ https://www.ncbi.nlm.nih.gov/pubmed/35353165 http://dx.doi.org/10.1001/jamanetworkopen.2022.4830

Ejemplares similares

Adjuvant chemotherapy compared with observation in patients with T2aN0 stage IB lung adenocarcinoma
por: Lee, Po-Hsin, et al.
Publicado: (2023)

Characteristics and immune checkpoint inhibitor effects on non-smoking non-small cell lung cancer with KRAS mutation: A single center cohort (STROBE-compliant)
por: Wu, Jia-Jun, et al.
Publicado: (2022)

Histological Transformation after Acquired Resistance to the Third-Generation EGFR-TKI in Patients with Advanced EGFR-Mutant Lung Adenocarcinoma
por: Lee, Po-Hsin, et al.
Publicado: (2022)

Intercalated Treatment Following Rebiopsy Is Associated with a Shorter Progression-Free Survival of Osimertinib Treatment
por: Tseng, Jeng-Sen, et al.
Publicado: (2018)

ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients
por: Chang, Gee-Chen, et al.
Publicado: (2020)

The Role of Neutrophil-to-Lymphocyte Ratio in Advanced EGFR-Mutant NSCLC Patients Treated with First-Line Osimertinib
por: Chen, Kuan-Chih, et al.
Publicado: (2023)

Higher CD4/CD8 ratio of pleural effusion predicts better survival for lung cancer patients receiving immune checkpoint inhibitors
por: Lee, Po-Hsin, et al.
Publicado: (2021)

Reactivation of Hepatitis B Virus in Lung Cancer Patients Receiving Tyrosine Kinase Inhibitor Treatment
por: Lee, Po-Hsin, et al.
Publicado: (2022)

Publisher Correction: The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M
por: Huang, Yen-Hsiang, et al.
Publicado: (2021)

The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M
por: Huang, Yen-Hsiang, et al.
Publicado: (2021)

PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment naïve advanced EGFR-mutant non-small cell lung cancer patients
por: Hsu, Kuo-Hsuan, et al.
Publicado: (2022)

The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan
por: Huang, Yen-Hsiang, et al.
Publicado: (2022)

Correction to: The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan
por: Huang, Yen-Hsiang, et al.
Publicado: (2022)

Various impacts of driver mutations on the PD-L1 expression of NSCLC
por: Chu, Cheng-Hsiang, et al.
Publicado: (2022)

The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma
por: Huang, Yen-Hsiang, et al.
Publicado: (2022)

The Association of Acquired T790M Mutation with Clinical Characteristics after Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma
por: Huang, Yen-Hsiang, et al.
Publicado: (2018)

Outcome of Thromboembolic Events and Its Influence on Survival Time of Advanced NSCLC Patients Treated with Antiangiogenic Therapy
por: Ou, Wei-Fan, et al.
Publicado: (2023)

EGFR mutation, smoking, and gender in advanced lung adenocarcinoma
por: Tseng, Chien-Hua, et al.
Publicado: (2017)

Primary Tumor Radiotherapy During EGFR-TKI Disease Control Improves Survival of Treatment Naïve Advanced EGFR-Mutant Lung Adenocarcinoma Patients
por: Hsu, Kuo-Hsuan, et al.
Publicado: (2021)

EGFR-activating mutations, DNA copy number abundance of ErbB family, and prognosis in lung adenocarcinoma
por: Chen, Hsuan-Yu, et al.
Publicado: (2016)

The emergence of T790M mutation in EGFR-mutant lung adenocarcinoma patients having a history of acquired resistance to EGFR-TKI: focus on rebiopsy timing and long-term existence of T790M
por: Tseng, Jeng-Sen, et al.
Publicado: (2016)

Comprehensive Analysis and Risk Identification of Pulmonary Cryptococcosis in Non-HIV Patients
por: Lin, Chun, et al.
Publicado: (2021)

Trends in Prevalence of Gout Among US Asian Adults, 2011-2018
por: Yokose, Chio, et al.
Publicado: (2023)

Influence of the Timing of Leptomeningeal Metastasis on the Outcome of EGFR-Mutant Lung Adenocarcinoma Patients and Predictors of Detectable EGFR Mutations in Cerebrospinal Fluid
por: Liao, Pei-Ya, et al.
Publicado: (2022)

Mutational monitoring of EGFR T790M in cfDNA for clinical outcome prediction in EGFR-mutant lung adenocarcinoma
por: Su, Kang-Yi, et al.
Publicado: (2018)

Characteristics of young lung cancer: Analysis of Taiwan's nationwide lung cancer registry focusing on epidermal growth factor receptor mutation and smoking status
por: Hsu, Chia-Hung, et al.
Publicado: (2016)

Comparison of Trends in Self-reported Cigarette Consumption and Sales in England, 2011 to 2018
por: Jackson, Sarah E., et al.
Publicado: (2019)

Association of smoking and ALK tyrosine-kinase inhibitors on overall survival in treatment-naïve ALK-positive advanced lung adenocarcinoma
por: Zheng, Zhe-Rong, et al.
Publicado: (2023)

Characteristics of Deaths Among Individuals in US Immigration and Customs Enforcement Detention Facilities, 2011-2018
por: Grassini, Molly, et al.
Publicado: (2021)

Patterns in Patient Encounters and Emergency Department Capacity in California, 2011-2021
por: Hsia, Renee Y., et al.
Publicado: (2023)

Identification of Five Driver Gene Mutations in Patients with Treatment-Naïve Lung Adenocarcinoma in Taiwan
por: Hsu, Kuo-Hsuan, et al.
Publicado: (2015)

Prior EGFR tyrosine-kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemonaïve patients with EGFR-mutant lung adenocarcinoma
por: Tseng, Jeng-Sen, et al.
Publicado: (2014)

Smokers’ Use of E-Cigarettes in Situations Where Smoking Is not Permitted in England: Quarterly Trends 2011–2020 and Associations With Sociodemographic and Smoking Characteristics
por: Jackson, Sarah E, et al.
Publicado: (2021)

Genome-Wide Epigenetic Landscape of Lung Adenocarcinoma Links HOXB9 DNA Methylation to Intrinsic EGFR-TKI Resistance and Heterogeneous Responses
por: Su, Sheng-Fang, et al.
Publicado: (2021)

Utilization Rates of Pancreatectomy, Radical Prostatectomy, and Nephrectomy in New York, Ontario, and New South Wales, 2011 to 2018
por: Pang, Hilary Y. M., et al.
Publicado: (2021)

Socio-Economic Status Differences in Changing Affordability of Tobacco Products from 2011–2012 to 2018–2019 in India
por: Sharma, Nitika, et al.
Publicado: (2022)

Evaluation of Secondhand Smoke Exposure in New York City Public Housing After Implementation of the 2018 Federal Smoke-Free Housing Policy
por: Thorpe, Lorna E., et al.
Publicado: (2020)

Higher frequency but random distribution of EGFR mutation subtypes in familial lung cancer patients
por: Hsu, Kuo-Hsuan, et al.
Publicado: (2016)

Trends in the Use of Opioids vs Nonpharmacologic Treatments in Adults With Pain, 2011-2019
por: Pritchard, Kevin T., et al.
Publicado: (2022)

Trends in the Age of Cigarette Smoking Initiation Among Young Adults in the US From 2002 to 2018
por: Barrington-Trimis, Jessica L., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_n2082b5kdrh1gfsp8ob3c56050